- Home
- IGMS vs AIRJ Comparison
IGMS vs AIRJ Comparison
Compare IGMS & AIRJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- AIRJ
- Stock Information
- Founded
- IGMS 1993
- AIRJ N/A
- Country
- IGMS United States
- AIRJ United States
- Employees
- IGMS N/A
- AIRJ N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- AIRJ
- Sector
- IGMS Health Care
- AIRJ
- Exchange
- IGMS Nasdaq
- AIRJ NYSE
- Market Cap
- IGMS 348.5M
- AIRJ 285.0M
- IPO Year
- IGMS 2019
- AIRJ N/A
- Fundamental
- Price
- IGMS $1.77
- AIRJ $9.04
- Analyst Decision
- IGMS Hold
- AIRJ Strong Buy
- Analyst Count
- IGMS 8
- AIRJ 1
- Target Price
- IGMS $6.14
- AIRJ $12.00
- AVG Volume (30 Days)
- IGMS 779.9K
- AIRJ 137.2K
- Earning Date
- IGMS 03-06-2025
- AIRJ 02-26-2025
- Dividend Yield
- IGMS N/A
- AIRJ N/A
- EPS Growth
- IGMS N/A
- AIRJ N/A
- EPS
- IGMS N/A
- AIRJ 4.07
- Revenue
- IGMS $2,918,000.00
- AIRJ N/A
- Revenue This Year
- IGMS $23.57
- AIRJ N/A
- Revenue Next Year
- IGMS $192.36
- AIRJ N/A
- P/E Ratio
- IGMS N/A
- AIRJ $2.22
- Revenue Growth
- IGMS 57.64
- AIRJ N/A
- 52 Week Low
- IGMS $1.59
- AIRJ $4.94
- 52 Week High
- IGMS $22.50
- AIRJ $49.11
- Technical
- Relative Strength Index (RSI)
- IGMS 19.54
- AIRJ 55.08
- Support Level
- IGMS $1.59
- AIRJ $7.35
- Resistance Level
- IGMS $2.06
- AIRJ $9.43
- Average True Range (ATR)
- IGMS 0.45
- AIRJ 0.88
- MACD
- IGMS -0.30
- AIRJ -0.04
- Stochastic Oscillator
- IGMS 3.27
- AIRJ 65.00
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About AIRJ MONTANA TECHNOLOGIES CORP
Montana Technologies Corp is engaged in transformational technology that provides significant energy efficiency gains in air conditioning and comfort cooling applications, as well as a potential source of potable water, all through its proprietary "AirJoule" unit.